HOME >> BIOLOGY >> NEWS
Evidence For Genetic Effects On The Behavior Of Normal Two-Week Old Babies

Dopamine D4 receptor and serotonin transporter promoter in the determination of neonatal temperament RP Ebstein, J Levine, V Geller, J Auerbach, I Gritsenko, RH Belmaker Research Laboratory, S. Herzog Memorial Hospital, P.O. Box 35300, Jerusalem 91351, Israel; Beersheva Mental Health Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, P.O. box 4600, Beersheva, Israel; Department of Behavioral Sciences, Ben-Gurion University of the Negev, Israel.

Many of the known human genes exist in variant or polymorphic forms that are distributed frequently in the general population. Some, but not all, recent studies have shown a contribution of such common genetic polymorphisms to the determination of adult human personality traits, especially novelty or sensation seeking and harm avoidance or neuroticism. Since marked deviations in adult personality traits might be potential risk factors for some psychiatric disorders such as alcoholism and depression, early identification of deviations in these temperaments might be important in the design of intervention strategies. A group of Israeli scientists reports in the current issue of Molecular Psychiatry (http://www.stockton-press.co.uk/mp/) on a study in which they used the Brazelton Neonatal Behavioral Assessment Scale (NBAS) to examine the contribution of the so-called novelty seeking' and the 'neuroticism' genes to the behavioral responses of 81 two-week old babies. Prof. Brazelton of Harvard Medical School designed the NBAS in order to evaluate the kind of person the newborn baby is. It assesses the baby's behavioral repertoire as he responds to human and non-human stimuli. The way the baby uses states of consciousness to control his or her responses reveals the baby's capacity to respond to his new environment. A statistically significant association was observed of variants of the dopamine D4 receptor gene previously shown by some investigators to
'"/>

Contact: Julie Vianello
J.vianello@stockton-press.co.uk
301-496-6979
Molecular Psychiatry
25-May-1998


Page: 1 2 3

Related biology news :

1. Evidence builds for potential new cancer drug target
2. Evidence for sympatric speciation by host shift in the sea
3. Evidence for the impact of climate change on deep-sea biodiversity
4. Evidence for fat hormone target in brain
5. Evidence of nanobacterial-like structures found in human calcified arteries and cardiac valves
6. Evidence shows the heart has stem cells able to regenerate muscle tissue lost to disease, wear
7. Evidence for orangutan culture
8. Evidence suggests that standard smallpox vaccine offers long-term immunity
9. Evidence that adults stem cells differentiate like embryonic stem cells published in Nature
10. When Shewanella meets goethite: Evidence found of recognition between animate and inanimate objects
11. Evidence links protein damage to Parkinsons

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Evidence For Genetic Effects The Behavior Normal Two Week Old Babies

(Date:4/13/2015)... CHICAGO , April 13, 2015  higi, a ... with ways to more fully engage with their communities ... its industry-leading, privacy protected and secure API.  ... API enables the most accessible, affordable, and convenient vehicle ... The API will ...
(Date:4/9/2015)... Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the third quarter of ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-438-5524 (conference ...
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
(Date:4/17/2015)... Houston, TX (PRWEB) April 17, 2015 ... genomics and proteomics technologies, announced today that it ... sequencing system, an innovative multiplex PCR based targeted ... ultra-high resolution sequence analysis, that enables accurate detection ... pending Relay-PCR™ and Omega-Primer™ technologies. The company will ...
(Date:4/16/2015)... 16, 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) ... quarter results on Thursday, April 30, 2015 at 4:00 ... will host a conference call at 4:30 PM Eastern ... company’s outlook for the future. , The conference call ... the homepage and in the Investor Relations section of ...
(Date:4/16/2015)... According to the 2014 Liberty ... source was ranked first among the leading causes ... lifting, pushing, pulling, holding, carrying, or throwing and ... David Round Company takes statistics like this very ... to develop and design equipment that prevents these ...
(Date:4/16/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... venture with G-treeBNT (ReGenTree LLC) has retained Ora, ... for the orphan disorder, neurotrophic keratopathy (NK), and ... syndrome (DES) in the U.S.  Both trials will ... year.  Each of these eye disorders was being ...
Breaking Biology Technology:LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
Cached News: